Overview

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

Status:
Not yet recruiting

Trial end date:
2025-12-20

Target enrollment:

Participant gender:

Summary

This is a randomized, multicenter, controlled study to compared the Efficacy and Safety of XELOX combined with Apatinib versus XELOX as post-operative chemotherapy in locally advanced gastric signet ring carcinoma with D2 dissection.

Phase:

Phase 3

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

Apatinib
Capecitabine
Oxaliplatin